Searched for
BIOTECH OFFERINGS
US stocks: S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on IranUS market saw a mixed close as the S&P 500 and Nasdaq dipped, primarily due to tech giants like Alphabet facing investor scrutiny over AI s...- When frontier AI can be switched off: India's sovereignty challengeIndia must not depend on foreign AI models, as US export controls demonstrate potential access denial. Past reliance on external tech, like...
- Five reforms India needs before the next shockIndia faces economic vulnerabilities from external crises. Five reforms are proposed to build resilience. These include reducing gold and c...
- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- As AI shifts from training to inference, Intel moves up the stackIntel is changing its AI strategy. The company is now focusing on building complete AI systems and infrastructure, not just chips. This mov...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian benchmark indices ended higher after a volatile session, with late buying in heavyweight IT stocks lifting sentiment. Sensex gained ...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- H-1B chill sets in; Flipkart doubles down on ShopsyUS demand for H-1B visas has slumped to a seven-year low amid steeper costs and Trump-era policy shifts. This and more in today’s ETtech To...
- IPO calendar: 3 companies set to launch public offers this week; check detailsThis comes as markets continue to witness sharp downswings and muted recoveries, with oil prices remaining elevated amid the seesaw politic...
- The ‘Inevitables’: Warren Buffett's framework for finding companies that will dominate for decadesWarren Buffett divided the investment universe into Inevitables, Highly Probables, and Impostors. The Inevitables are companies whose domin...
- Why SpaceX's mega IPO may not signal a broader rebound in listingsSpaceX's huge IPO is set to capture global attention. However, experts believe this event may not reflect the true health of the broader IP...
- Global Market: Hong Kong IPO boom draws rising interest from overseas companiesHong Kong's stock market is seeing more foreign companies file for listings. Firms from countries like Indonesia and South Korea are explor...
- Want to jump into the 'China is back' rally? Tread carefullyInvestors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...
- Flipkart puts IPO on ice; Rapido's $240 million raiseFlipkart has hit pause on its IPO in a jittery market. This and more in today's ETtech Top 5.
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
Load More
